ClinicalTrials.gov
public full text
Public Domain
A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors
Indinavir is usually taken three times a day. The purpose of this study is to see if it is safe and effective to take indinavir only twice a day plus nelfinavir (also taken twice a day) and efavirenz (taken once a day).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Same-Day Treatment With Genvoya vs. EFV/TDF/3TC#1153737
- Pilot Assessment of Lopinavir/Ritonavir and Maraviroc#1137317
- Safety of Prasaprohyai 95%Ethanolic Extract Capsules in Healthy Volunteer#904460
- The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study#806717
- An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis#865692
Record · ID 881227
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive